Trial · NCT05019521
Adverse events1,250
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,250
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Neovascular age-related macular degeneration | Eye disorders | Primary Evaluation Period: Danicopan 100 mg BID | 5 | 93 | |
| other | Neovascular age-related macular degeneration | Eye disorders | Primary Evaluation Period: Danicopan 200 mg BID | 5 | 91 | |
| other | Neovascular age-related macular degeneration | Eye disorders | Primary Evaluation Period: Danicopan 400 mg QD | 5 | 91 | |
| other | Neovascular age-related macular degeneration | Eye disorders | Primary Evaluation Period: Placebo | 3 | 90 | |
| other | Neovascular age-related macular degeneration | Eye disorders | Secondary Evaluation Period: Danicopan 100 mg BID | 3 | 73 | |
| other | Neovascular age-related macular degeneration | Eye disorders | Secondary Evaluation Period: Danicopan 200 mg BID | 2 | 67 | |
| other | Neovascular age-related macular degeneration | Eye disorders | Secondary Evaluation Period: Danicopan 400 mg QD | 1 | 73 | |
| other | Neovascular age-related macular degeneration | Eye disorders | Secondary Evaluation Period: Placebo - Danicopan 100 mg BID | 1 | 24 | |
| other | Neovascular age-related macular degeneration | Eye disorders | Secondary Evaluation Period: Placebo - Danicopan 200 mg BID | 1 | 23 | |
| other | Neovascular age-related macular degeneration | Eye disorders | Secondary Evaluation Period: Placebo - Danicopan 400 mg QD | 1 | 23 | |
| other | Nausea | Gastrointestinal disorders | Primary Evaluation Period: Danicopan 100 mg BID | 5 | 93 | |
| other | Nausea | Gastrointestinal disorders | Primary Evaluation Period: Danicopan 200 mg BID | 3 | 91 | |
| other | Nausea | Gastrointestinal disorders | Primary Evaluation Period: Danicopan 400 mg QD | 4 | 91 | |
| other | Nausea | Gastrointestinal disorders | Primary Evaluation Period: Placebo | 3 | 90 | |
| other | Nausea | Gastrointestinal disorders | Secondary Evaluation Period: Danicopan 100 mg BID | 3 | 73 | |
| other | Nausea | Gastrointestinal disorders | Secondary Evaluation Period: Danicopan 200 mg BID | 1 | 67 | |
| other | Nausea | Gastrointestinal disorders | Secondary Evaluation Period: Danicopan 400 mg QD | 0 | 73 | |
| other | Nausea | Gastrointestinal disorders | Secondary Evaluation Period: Placebo - Danicopan 100 mg BID | 0 | 24 | |
| other | Nausea | Gastrointestinal disorders | Secondary Evaluation Period: Placebo - Danicopan 200 mg BID | 0 | 23 | |
| other | Nausea | Gastrointestinal disorders | Secondary Evaluation Period: Placebo - Danicopan 400 mg QD | 1 | 23 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05019521/events